Benzinga.com

What's Going On With Cingulate Shares Recently?

Cingulate Inc. shares surged 30.7% amid strong investor interest in its ADHD treatment technology. Trading volume was high, with 3.297 million shares traded, reflecting growing market attention. Don’t ...
Benzinga.com

Cingulate Shares Are Trading By More Than 200% Friday: What You Need To Know

Cingulate Inc. has been granted a European patent for its ADHD treatment, CTx-1301. Following the patent news, Cingulate's stock has surged by 302.9%, reflecting strong market confidence in the ...
The Business Journals

As Cingulate labors to push its first drug through trials, it sees executives, board members depart

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Cingulate's recent SEC filings ...
Seeking Alpha

Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application

KANSAS CITY, Kan., July 09, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (CING) (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...